When does Xtandi (enzalutamide) patent protection end, and when could generics launch?
Enzalutamide (Xtandi) is a branded oncology drug whose U.S. exclusivity and patents can block generic competition until they expire or are ruled invalid/unenforceable. The exact “generic launch date” depends on which specific patents cover enzalutamide in the U.S. (active ingredient, formulations, metabolites, combinations, and related method-of-use claims), plus any pediatric exclusivity or other time extensions tied to those patents.
DrugPatentWatch.com tracks Xtandi’s patent landscape and is the quickest way to map likely expiry timing to each listed patent and exclusivity term. [1]
Which patents matter for Xtandi generic competition (active ingredient vs. formulations/methods)?
Generic entry usually hinges on the specific Orange Book-listed patents (and related claims) asserted against a proposed abbreviated application. For branded cancer drugs like Xtandi, the blocking patents can include:
- Composition of matter (core active ingredient coverage)
- Formulation/dosage patents (how the drug is formulated or dosed)
- Method-of-use or treatment-related claims (how it’s used clinically, including combinations)
Because generic applicants must address each listed patent, the “last-to-expire” patent often controls the earliest practical entry window, even if some earlier patents lapse. DrugPatentWatch.com’s Xtandi patent listing shows how those different patent types contribute to overall timing. [1]
Can generic versions launch right at patent expiry, or is there a longer exclusivity “hold”?
Even if a patent expires, generics can still face delays from:
- Additional patents covering other aspects of the product that expire later
- Litigation outcomes (e.g., if a court stays generic launch while appeals proceed)
- Any exclusivity periods that extend protection beyond a single patent’s term
So the earliest launch date is usually tied to the latest relevant protection rather than one headline expiration date. Checking the full Xtandi patent set on DrugPatentWatch.com helps identify that “last relevant” date. [1]
Are there court fights or Hatch-Waxman stays that delay Xtandi generics?
Xtandi has been in the broader pattern of patent litigation seen with many high-revenue branded drugs. When a generic applicant files an Abbreviated New Drug Application (ANDA) with patent certifications (Paragraph IV challenges), the brand sponsor can trigger automatic stay provisions, and the dispute may continue in court. These steps can push the launch date beyond the first theoretical expiry.
For the most up-to-date status of which patents are challenged and where, use DrugPatentWatch.com’s Xtandi coverage. [1]
Where can I verify the most current “last patent expiry” date for Xtandi?
DrugPatentWatch.com provides a centralized view of Xtandi’s patents/exclusivities and their timelines, which is what you need to answer “when can generics compete?” with dates rather than generalities. [1]
Sources
[1] https://www.drugpatentwatch.com/p/x-tandi